The converstations part on the new version is getting some traffic. You should go elsewhere now, it looks like yahoo is going to keep it fubar with some going to the new version, and some coming here.
EVERY biotech stock I've watched over the years went down just before news was expected. Even when FDA did approve a drug, the stock did the same thing. I've never understood why.
Maybe short term traders were riding the uptick for fast profits, and don't want to take a chance on the trials, so they take their fast profit to the next short term.
Or, since volume is getting lower, shorts are driving it down so they can cover, or someone is driving it down so they can get more.
The one sure answer is, manipulation. It is frustrating. Especially considerin the company could do a PR saying the preliminary results are very encouraging and help us out.
It could just be that the hedge fund that they sold their soul to in May knows the results of the trials are coming back..... other than perfect.
it's pretty much a given that the warrants from May were exercised at .43. Imagine. 7M shares sold at .43
I wonder why. If they plan on selling the news and taking profit, which will create a pull back after news is released, or if they are expecting bad results and want to sell while they can.
It started out like a Beta, now I cannot turn it off, and I HATE IT
If you really want a time frame. A PR said patient enrollment had completed June 6. Give another week or two to finish those cases. June 20. Add 1 month to make sure there are no bad after affects. July 20. Add two weeks to compile the data and make a formal presentation and write up an PR. August 3. Add another week just for sheets and grins. August 10. They like to PR on Monday, August 15.
Mid August, and that is being optimistic.
Expect results sometime in August, maybe even September. Those types of reports and results seem to always lag behind expectations, and the general concensus is almost always very optimistic.
AC5 is far superior to Xcede. In just a few minutes of looking at their product, I can see numerous shortcomings when compared to AC5. The product has to be cut to size, which is time consuming. Xcede has adhesive on the back - #$%$ what happens if it isn't perfectly placed?. What about areas of the body that aren't flat, or are close to other structures? Compare that to squirting or spraying a liquid, and moving on with the procedure.
Sorry to be the bearer of bad news, but if you cannot understand why DYSL is a "sleeper" compared to ARTH, then you don't fully understand the products of the two companies. That's where DD comes into play.
It's fractal dimensions. He is good at using them to predict turnarounds. We all knew it wouldn't keep running and running without news, so a pullback wasn't a surprise. The fact he predicted it that close was impressive to me.
The fact it dipped like it did, and came back is very encouraging. I hope we get news next week.
I subscribe to Michael Murphy's service. Last night, his Radar Report said " It is due for a 38.2% pullback of the move from 40 cents to 91 cents. That works out to a 71 or 72 cent target."
And NAILED it.
They are desperate, and that is all that have. Let them act like fools, we'll laugh all the way to the bank.
You are right, they don't have a product. I'll add, there is no guarantee they will get approval. You should wait until US approval, when they DO have a product, and buy stock then. Not until.